Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Differential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation.

Lewis WR, Fonarow GC, LaBresh KA, Cannon CP, Pan W, Super DM, Sorof SA, Schwamm LH.

Am J Cardiol. 2009 Jan 15;103(2):227-31. doi: 10.1016/j.amjcard.2008.08.062. Epub 2008 Nov 7.

2.

Liver fatty acid binding protein and mitogenesis in transfected hepatoma cells.

Keler T, Khan S, Sorof S.

Adv Exp Med Biol. 1997;400A:517-24. Review. No abstract available.

PMID:
9547599
3.

Modulation of mitogenesis by liver fatty acid binding protein.

Sorof S.

Cancer Metastasis Rev. 1994 Dec;13(3-4):317-36. Review.

PMID:
7712594
5.

Growth promotion of transfected hepatoma cells by liver fatty acid binding protein.

Keler T, Sorof S.

J Cell Physiol. 1993 Oct;157(1):33-40.

PMID:
8408240
6.
7.
8.

Specific high affinity binding of lipoxygenase metabolites of arachidonic acid by liver fatty acid binding protein.

Raza H, Pongubala JR, Sorof S.

Biochem Biophys Res Commun. 1989 Jun 15;161(2):448-55.

PMID:
2500117
9.
10.

Late target protein of the carcinogen N-2-fluorenylacetamide in rat liver.

Munir KM, Blackburn GR, Sorof S.

Cancer Res. 1988 Dec 1;48(23):6745-52.

11.

Liver fatty acid binding protein is the mitosis-associated polypeptide target of a carcinogen in rat hepatocytes.

Bassuk JA, Tsichlis PN, Sorof S.

Proc Natl Acad Sci U S A. 1987 Nov;84(21):7547-51.

13.
14.
15.
16.
17.

Normal liver chromatin contains a firmly bound and larger protein related to the principal cytosolic target polypeptide of a hepatic carcinogen.

Vinores SA, Churey JJ, Haller JM, Schnabel SJ, Custer RP, Sorof S.

Proc Natl Acad Sci U S A. 1984 Apr;81(7):2092-6.

18.

Persistence of precursor cells of squamous metaplasia in preneoplastic mammary outgrowth lines from mice.

Schaefer FV, Custer RP, Sorof S.

J Natl Cancer Inst. 1984 Jan;72(1):185-9.

PMID:
6582297
19.

Nononcogenic hormone-independent alveoli produced by carcinogens in cultured mouse mammary glands.

Schaefer FV, Tonelli QJ, Dickens MS, Custer RP, Sorof S.

Cancer Res. 1983 Jul;43(7):3310-5.

21.
22.

Principal polypeptide target of carcinogen at the beginning of liver carcinogenesis by three carcinogens.

Blackburn GR, Schnabel SJ, Danley JM, Hogue-Angeletti RA, Sorof S.

Cancer Res. 1982 Nov;42(11):4664-72. No abstract available.

23.

General process of induction of squamous metaplasia by cyclic adenine nucleotide and prostaglandins: mouse prostate glands.

Schaefer FV, Custer RP, Sorof S.

Cancer Res. 1982 Sep;42(9):3682-7. No abstract available.

24.

Induction of biochemical differentiation in three-dimensional collagen cultures of mammary epithelial cells from virgin mice.

Tonelli QJ, Sorof S.

Differentiation. 1982;22(3):195-200. No abstract available.

PMID:
6757034
25.

Early events during liver carcinogenesis involving two carcinogen:protein complexes.

Blackburn GR, Andrews JP, Custer RP, Sorof S.

Cancer Res. 1981 Oct;41(10):4039-49. No abstract available.

26.

Lack of induction of murine mammary tumor virus expression in cultured mammary glands treated with chemical carcinogens.

Tonelli QJ, Long CA, Vaidya AB, Sorof S.

Int J Cancer. 1981 Jun 15;27(6):811-7. No abstract available.

PMID:
6270025
27.
29.

An early event associated with liver carcinogenesis involving loss of a polypeptide that binds carcinogen.

Blackburn GR, Andrews JP, Rao KV, Sorof S.

Cancer Res. 1980 Dec;40(12):4688-93.

30.

Induction of abnormal development and differentiation in cultured mammary glands by cyclic adenine nucleotide and prostaglandins.

Schaefer FV, Custer RP, Sorof S.

Nature. 1980 Aug 21;286(5775):807-10. No abstract available.

PMID:
6157108
31.

Retinoid prevents transformation of cultured mammary glands by procarcinogens but not by many activated carcinogens.

Dickens MS, Sorof S.

Nature. 1980 Jun 19;285(5766):581-4. No abstract available.

PMID:
6772960
32.

Epidermal growth factor requirement for development of cultured mammary gland.

Tonelli QJ, Sorof S.

Nature. 1980 May 22;285(5762):250-2.

PMID:
6966378
33.

Retinoid prevents mammary gland transformation by carcinogenic hydrocarbon in whole-organ culture.

Dickens MS, Custer RP, Sorof S.

Proc Natl Acad Sci U S A. 1979 Nov;76(11):5891-5.

34.

Transformation of cultured mouse mammary glands by aromatic amines and amides and their derivatives.

Tonelli QJ, Custer RP, Sorof S.

Cancer Res. 1979 May;39(5):1784-92. No abstract available.

35.

Carcinogen-protein complexes in hamster colon and glandular stomach during long-term administration of 3-methylcholanthrene.

Brodsky LH, Feinberg RF, Sorof S.

Cancer Res. 1978 Jun;38(6):1654-60. No abstract available.

36.

Carcinogen-protein complexes in mammary gland after administration of 3-methylcholanthrene.

Dickens MS, Sorof S.

Biochem Biophys Res Commun. 1977 Dec 7;79(3):713-9. No abstract available.

PMID:
597300
37.

Carcinogen-protein complexes in liver during hepatocarcinogenesis by aflatoxin B1(1).

Mainigi KD, Sorof S.

Cancer Res. 1977 Dec;37(12):4304-12. No abstract available.

38.

Evidence for a receptor protein of activated carcinogen.

Mainigi KD, Sorof S.

Proc Natl Acad Sci U S A. 1977 Jun;74(6):2293-6.

39.

Cyclic AMP phosphodiesterase inhibitors depress production of plasminogen activator by Chinese hamster ovary cells.

Mott DM, Fabisch PH, Sorof S.

Biochem Biophys Res Commun. 1976 Jun 21;70(4):1150-6. No abstract available.

PMID:
182161
40.

High extracellular fibrinolytic activity of tumors and control normal tissues.

Chibber BA, Niles RM, Prehn L, Sorof S.

Biochem Biophys Res Commun. 1975 Jul 22;65(2):806-12. No abstract available.

PMID:
167785
41.

Lack of correlation between fibrinolysis and the transformed state of cultured mammalian cells.

Mott DM, Fabisch PH, Sani BP, Sorof S.

Biochem Biophys Res Commun. 1974 Nov 27;61(2):621-7. No abstract available.

PMID:
4375992
42.

Properties of the principal liver target protein of a hepatic carcinogen.

Sani BP, Mott DM, Jasty V, Sorof S.

Cancer Res. 1974 Oct;34(10):2476-81. No abstract available.

43.

Isolation and properties of the principal liver protein conjugate of a hepatic carcinogen.

Sorof S, Sani BP, Kish VM, Meloche HP.

Biochemistry. 1974 Jun 4;13(12):2612-20. No abstract available.

PMID:
4208844
44.

Nonidentity of liver alcohol dehydrogenase and the principal protein target of hepatic azocarcinogen.

Sani BP, Mott DM, Sorof S.

Biochem Biophys Res Commun. 1974 Feb 4;56(3):732-8. No abstract available.

PMID:
4207906
45.

The content of the principal protein target of a hepatic carcinogen in liver tumors.

Mott DM, Sani BP, Sorof S.

Cancer Res. 1973 Nov;33(11):2721-5. No abstract available.

46.

The principal liver carcinogen-protein conjugate after a single dose of hepatic azocarcinogen.

Sorof S, Young EM.

Cancer Res. 1973 Sep;33(9):2010-3. No abstract available.

47.

Detection of the principal protein target of a hepatic carcinogen.

Sani BP, Mott DM, Szajman SM, Sorof S.

Biochem Biophys Res Commun. 1972 Dec 18;49(6):1598-604. No abstract available.

PMID:
4629562
48.

Purification and properties of the principal liver protein conjugate of a hepatic carcinogen.

Sorof S, Kish VM, Sani B.

Biochem Biophys Res Commun. 1972 Aug 21;48(4):860-5. No abstract available.

PMID:
4629096
49.

Abnormal size profiles of soluble macromolecules from azo-dye liver tumors.

Sorof S, Young EM, McBride RZ, Coffey CB.

J Natl Cancer Inst. 1971 Feb;46(2):275-80. No abstract available.

PMID:
5000539
50.

On protein targets of chemical carcinogens: dissimilar molecular sizes of the principal protein conjugates.

Sorof S, Young EM, McBride RA, Coffey CB.

Cancer Res. 1970 Jul;30(7):2029-34. No abstract available.

Supplemental Content

Support Center